Introduction Premature ejaculation (PE) is a highly prevalent and complex syndrome that
remains poorly defined and inadequately characterized. Pharmacotherapy represents the …

Premature ejaculation is the most common form of sexual dysfunction among men. The
pathophysiology of premature ejaculation appears to be multifactorial, implicating the need …

Introduction It is controversial whether or not the most frequent male sexual dysfunctions,
premature ejaculation (PE) and erectile dysfunction (ED), share pathogenetic mechanisms …

Purpose To clarify the efficacy of phosphodiesterase-5 inhibitors (PDE5Is) and selective
serotonin reuptake inhibitors (SSRIs) in men with premature ejaculation (PE). Methods We …

Study Type–Therapy (RCT) Level of Evidence 1b What's known on the subject? and What
does the study add? Several authors have reported their experience with PDE5 inhibitors …

Purpose The purpose of the study was to conduct a systematic evaluation of the different
general prescribed drugs for premature ejaculation (PE). Methods A systematic literature …

Abstract Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for
erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine …

Premature ejaculation (PE) is considered to be the most common male sexual dysfunction.
The realization that PE may co-exist with ED prompted the use of PDE5-i's alone or in …

The parameters of vibrators used for sexual stimulation in laboratory settings and
therapeutic contexts are usually unknown. The unidentified range of vibrator characteristics …

Introduction The place of phosphodiesterase type 5 inhibitors (PDE5-Is) in treating
premature ejaculation (PE) remains a therapeutic challenge. Objectives (1) To summarize …